Free Access
Med Sci (Paris)
Volume 33, Number 6-7, Juin-Juillet 2017
Page(s) 567 - 569
Section Nouvelles
Published online 19 July 2017
  1. Longnecker RM, Kieff E, Cohen JI. In: Fields Virology, 6. USA: Lippincott Williams and Wilkins, 2013 : 2455. [Google Scholar]
  2. Delecluse HJ, Feederle R, O’Sullivan B, et al. Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol 2007 ; 60 : 1358–1364. [CrossRef] [PubMed] [Google Scholar]
  3. Busson P, Ooka T, Marilys Corbex M. Carcinomes nasopharyngés associés au virus d’Epstein-Barr. Med Sci (Paris) 2004 ; 20 : 453–457. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Klinke O, Feederle R, Delecluse HJ. Genetics of Epstein-Barr virus microRNAs. Semin Cancer Biol 2014 ; 26 : 52–59. [CrossRef] [PubMed] [Google Scholar]
  5. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001 ; 345 : 1877–1882. [CrossRef] [PubMed] [Google Scholar]
  6. Tsai MH, Raykova A, Klinke O, et al. Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell rep 2013 ; 5 : 458–470. [CrossRef] [PubMed] [Google Scholar]
  7. Shumilov A, Tsai MH, Schlosser YT, et al. Epstein-Barr virus particles induce centrosome amplification and chromosomal instability. Nat Commun 2017 ; 8 : 14257. [CrossRef] [PubMed] [Google Scholar]
  8. Feederle R, Neuhierl B, Baldwin G, et al. Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes. J Virol 2006 ; 80 : 9435–9443. [CrossRef] [PubMed] [Google Scholar]
  9. Levine MS, Bakker B, Boeckx B, et al. Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. Dev Cell 2017 ; 40 : 313–22.e5. [CrossRef] [PubMed] [Google Scholar]
  10. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007 ; 196 : 1749–1753. [CrossRef] [PubMed] [Google Scholar]
  11. Pavlova S, Feederle R, Gartner K, et al. An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA. J Virol 2013 ; 87 : 2011–2022. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.